Klinische Studie
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma(LEAP-015)Ph 3, Study to Evaluate the Efficacy and Safety of Lenvatinib + Pembrolizumab + Chemo Compared with Standard of Care Therapy as I-line in Pat. with Advanced/Metast. Gastroesophageal AdenoCA
Krankheitsentität(en)
Magen
StudientypInterventionsstudiePhase III
StudientypInterventionsstudiePhase III
Wesentliche EinschlusskriterienHistologically and/or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic geastroesophageal adenocarcinoma
Not HER 2 positiv
Is not expected to require tumor resection during the treatment course
Wesentliche AusschlusskriterienHas Had previous therapy for locally advanced unresectable or metastatic gastric/GEJ/ esophageal adenovarcinoma.
Has Haed major surgery within 28 days prior to first dose
Has known CNS metastases
Statusrekrutierend
Ansprechpartner & KontaktUniversitätsklinikum RegensburgInnere Medizin IStudienzentrale0941 9447063studienzentrum.innere1(at)ukr.de